TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment

Reuters

06-04

TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment

TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540214063"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540214063\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540214063?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540214063","market":"nz","top_or_hot":-1,"title":"TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-04 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL1TCJPm:1","article_id":"2540214063","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540214063","pubTimestamp":1749038491,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TriSalus Life Sciences Inc. has announced the launch of the TriNav FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"TriSalus Life Sciences推出TriNav FLX输注系统，可增强实体瘤治疗的可追踪性和精确度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLSI":0.9},"content_text":"TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n    \n\n        TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}